Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Extreme Prematurity

Extreme Prematurity

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Extreme Prematurity

5 trials tracked for Extreme Prematurity: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 322 citations.

5Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Other / NA 4
  1. Phase 3 Preterm Erythropoietin Neuroprotection Trial (PENUT Trial) Completed · 322 cited
  2. N/A Use of NIRS in Preterm Population Born at Altitude Completed
  3. N/A Therapist Education and Massage for Parent Infant-Outcomes Completed
  4. N/A Time to Accurate Heart Rate on Neonatal Outcomes Completed
  5. N/A Sustained Aeration of Infant Lungs Trial Completed

Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Extreme Prematurity: what the trials found

In a large-scale Phase 3 trial involving 941 participants, the administration of Epo did not significantly reduce the number of deaths or severe neurodevelopmental impairments (NDI) at 22-26 months corrected age (p=0.05).

The use of Epo was also associated with no statistically significant difference in the occurrence of serious adverse events (SAE) compared to the control group (p=0.05). Additionally, imaging results showed no significant differences between groups (p=0.36).

Recent results — preliminary, needs further review

  • Near-infrared spectroscopy (NIRS) utilization is currently under investigation but not yet corroborated.
  • The use of iRes Warmer with ResusView is currently under investigation but not yet corroborated.
  • Therapist Education and Massage for Parents of Extremely Preterm Infants showed high levels of parental recommendation (100%) and adherence (87%), though these are not yet corroborated.
  • Sustained Inflation is currently under investigation but not yet corroborated.

For the clinician treating this condition

  • Epo administration does not demonstrate a statistically significant impact on mortality or severe neurodevelopmental impairment in infants with extreme prematurity.
  • Epo treatment is associated with no significant difference in the rate of serious adverse events compared to standard care.

AI synthesis of 0 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.